Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimally invasive pancreatectomy with mesentericoportal venous resection: Results from a French national cohort.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

No-scalpel vasectomy: What is the learning curve?

The French journal of urology·2026
Same author

Outcomes of Liver Transplant Versus Partial Hepatectomy for Perihilar Cholangiocarcinoma Patients Requiring Arterial Reconstruction.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Environmental footprint of open versus laparoscopic inguinal hernia repair.

Hernia : the journal of hernias and abdominal wall surgery·2026
Same author

Predicting Best Performers After Minimally Invasive Left Pancreatectomy: Insights From a National Cohort.

Annals of surgery·2026
Same author

Phytotherapies and complementary therapies for erectile dysfunction: A focused secondary synthesis and critical clinical interpretation of the AFU/SFMS evidence base.

The French journal of urology·2026

Related Experiment Video

Updated: Jun 25, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Erectile dysfunction in end-stage liver disease men.

Eric Huyghe1, Nassim Kamar, Fabien Wagner

  • 1Department of Urology and Andrology, University Hospital, CHU Rangueil, 31059 Toulouse cedex 9, France. eric.huyghe@yahoo.fr

The Journal of Sexual Medicine
|February 12, 2009
PubMed
Summary

Erectile dysfunction (ED) is highly prevalent in men with end-stage liver disease (ESLD) awaiting transplantation. Key risk factors include alcohol, tobacco, and cardiovascular disease, necessitating targeted interventions for improved sexual health.

Related Experiment Videos

Last Updated: Jun 25, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Urology
  • Hepatology
  • Transplantation Medicine

Background:

  • Erectile dysfunction (ED) is a significant concern for men.
  • Data on ED in men with end-stage liver disease (ESLD) is scarce, with unknown risk factors.
  • Understanding ED in ESLD patients is crucial for improving their quality of life.

Purpose of the Study:

  • To investigate the prevalence, timeline, and risk factors of ED in patients with ESLD considered for liver transplantation.
  • To identify specific patient characteristics associated with sexual dysfunction in this population.

Main Methods:

  • A mailed survey was distributed to 123 eligible men awaiting liver transplantation.
  • 98% of eligible patients completed the questionnaire assessing sexual function.
  • The International Index of Erectile Function (IIEF-5) and Treatment-Satisfaction Scale (TSS) were used to evaluate erectile quality and sexual satisfaction.

Main Results:

  • 29% of patients were not sexually active; 74% of sexually active patients had ED.
  • Half of patients reported ED onset within six months.
  • Risk factors for ED included alcohol intake, tobacco use, and cardiovascular disease.
  • Viral hepatitis and cardiovascular disease were linked to lower sexual satisfaction.

Conclusions:

  • Men with ESLD awaiting liver transplantation exhibit high rates of inactivity, ED, and low sexual satisfaction.
  • Targeted interventions are needed to improve sexual functioning in this patient group.
  • Further validation through prospective trials with comprehensive questionnaires is recommended.